Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 3082 · Evidence-Based Drug Policy Act of 2025 ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

21 U.S.C. § 1703 Appointment and duties of Director and Deputy Directors

+0 −5Shown
More for 21 U.S.C. § 1703
Read § 1703Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 704(b)(12) of the Office of National Drug Control Policy Reauthorization Act of 1998 (21 U.S.C. 1703(b)(12)) is repealed.

§ 1703(b)Responsibilities(11)–(14)

Start of § 1703 to (b)(10) unchanged ·

(11) may serve as spokesperson of the Administration on drug issues;

(12) [struck: shall ensure that no Federal funds appropriated to the Office of National Drug Control Policy shall be expended for any study or contract relating to the legalization (for a medical use or any other use) of a substance listed in schedule I of section 812 of this title and take such actions as necessary to oppose any attempt to legalize the use of a substance (in any form) that—]

[struck: (A)] [struck: is listed in schedule I of section 812 of this title; and]

[struck: (B)] [struck: has not been approved for use for medical purposes by the Food and Drug Administration;]

(13) Repealed. Pub. L. 115–271, title VIII, § 8221(b)(1)(A), Oct. 24, 2018, 132 Stat. 4142.

(14) shall submit to the appropriate congressional committees on an annual basis, not later than 60 days after the date of the last day of the applicable period, a summary of—

Rest of § 1703 unchanged ·

Step through the changes